Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif., Feb. 15, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) today reported financial ...

Good afternoon. Thank you for attending today's 10x Genomics Fourth Quarter and Full Year 2022 Earnings Conference Call. My name is Bethany, and I will be the moderator for today's call. All lines ...

After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used gene ...

10x Genomics has begun commercial shipping of its long-awaited Visium HD Spatial Gene Expression instrument this week, a next-generation version of the company’s Visium spatial biology tool, two years ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...

Justin McAnear: So, Europe had a solid quarter this past quarter. And I think there’s probably a number of reasons for that. I think looking at the year-over-year compare, it was a favorable compare ...

Feb 6 (Reuters) - Genomics company 10x (TXG.O), opens new tab and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, ...

"The clear highlight of 2022 was the velocity of our innovation engine as our team delivered catalytic launches across all three platforms," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We ...

Operator: Good afternoon. Thank you for attending today's 10x Genomics Fourth Quarter and Full Year 2022 Earnings Conference Call. My name is Bethany, and I will be the moderator for today's call. - ...